184 related articles for article (PubMed ID: 31393905)
1. Empowering therapeutic antibodies with IFN-α for cancer immunotherapy.
Guo J; Xiao Y; Iyer R; Lu X; Lake M; Ladror U; Harlan J; Samanta T; Tomlinson M; Bukofzer G; Donawho C; Shoemaker A; Huang TH
PLoS One; 2019; 14(8):e0219829. PubMed ID: 31393905
[TBL] [Abstract][Full Text] [Related]
2. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
3. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells.
Lim JY; Gerber SA; Murphy SP; Lord EM
Cancer Immunol Immunother; 2014 Mar; 63(3):259-71. PubMed ID: 24357146
[TBL] [Abstract][Full Text] [Related]
4. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
5. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
[TBL] [Abstract][Full Text] [Related]
6. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
8. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
9. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.
Tähtinen S; Kaikkonen S; Merisalo-Soikkeli M; Grönberg-Vähä-Koskela S; Kanerva A; Parviainen S; Vähä-Koskela M; Hemminki A
PLoS One; 2015; 10(6):e0131242. PubMed ID: 26107883
[TBL] [Abstract][Full Text] [Related]
10. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
11. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking.
Dufour JH; Dziejman M; Liu MT; Leung JH; Lane TE; Luster AD
J Immunol; 2002 Apr; 168(7):3195-204. PubMed ID: 11907072
[TBL] [Abstract][Full Text] [Related]
13. m
Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
[TBL] [Abstract][Full Text] [Related]
15. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
Kapp K; Volz B; Curran MA; Oswald D; Wittig B; Schmidt M
J Immunother Cancer; 2019 Jan; 7(1):5. PubMed ID: 30621769
[TBL] [Abstract][Full Text] [Related]
16. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
18. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells.
Padovan E; Spagnoli GC; Ferrantini M; Heberer M
J Leukoc Biol; 2002 Apr; 71(4):669-76. PubMed ID: 11927654
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
